Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2018

View Archived Issues

European approval recommended for Perjeta as post-surgery treatment of HER2-positive breast cancer

4DMT and Roche expand ophthalmology partnership

Rhopressa launched in the U.S. for lowering intraocular pressure

Trogarzo becomes available in the U.S.

Novel PD-1/GITRL bispecific fusion proteins demonstrate antitumor activity in vivo

Crescendo Biologics completes Series B financing

GlaxoSmithKline reflects on accomplishments of first quarter 2018

Starpharma completes rolling NDA submission for VivaGel BV

MedImmune presents novel bivalent bispecific antibody MEDI-1109

Kodiak Sciences describes KSI-301, an anti-VEGF therapy with extended half-life

Shire offers overview of first quarter 2018

MEN-1611 demonstrates promising in vivo activity in various cancer models

Symphogen initiates first-in-human study of Sym-022 in advanced solid tumors or lymphomas

FDA grants QIDP and fast track designations to oral SCY-078 for vulvovaginal candidiasis

AbbVie submits European MAA for risankizumab in moderate to severe plaque psoriasis

Spark Therapeutics sells priority review voucher to Jazz Pharmaceuticals

FDA approves Kymriah for relapsed or refractory large B-cell lymphoma

DKFZ patents novel KLK6 inhibitors

Genocea files IND for phase I/IIa study of GEN-009

Lactobacillus reuteri may reduce bone loss in older women

Hetero Labs divulges betulinic acid analogues for HIV infection

FDA approves Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant melanoma

Actelion seeks FDA approval of Opsumit for inoperable chronic thromboembolic pulmonary hypertension

FDA grants priority review to sBLA for Keytruda

AbbVie presents BRD4 inhibitors

DCB discovers type III TKIs for cancer

Roche reflects on accomplishments of first quarter 2018

Aptevo submits IND for phase I study of APVO-436 in AML and MDS

Exicure reports phase I data on AST-005 in plaque psoriasis

FDA clears Pluristem's IND application for PLX-R18 to treat acute radiation syndrome

Capricor initiates phase II HOPE-2 trial of CAP-1002 in Duchenne muscular dystrophy

FDA grants fast track designation to ACE-083 for facioscapulohumeral muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...